

Subject Index, 1986

Vol. 36, Nos. 1-6

A

Adams, Lane W., an appreciation, 66-68

Adjuvant therapy, 42-47

- For breast cancer, 42-47
 - Adverse effects of, 46
 - Chemotherapy, 44-45; 59-60 (letters)
 - Endocrine therapy, 44
- For colorectal cancer, 352-355, 363-364
 - Postoperative irradiation, 352-355
 - Surgical adjuvant chemotherapy, 363-364

Analgesics, for cancer pain, 200, 202-209

B

Biopsy, needle aspiration, 69-82

- Classic paper on, 71-82
 - Histological interpretation, 78-80
 - Indications and advantages, 71-72
 - Preparation of the specimen, 73-74, 78
 - Technique, 72
 - Value of, 80-82
- An introduction, 69-70

Bladder cancer

- Incidence of, 16, 23, 30, 33-34, 39, 41
- Mortality of, 11, 15, 17
- Survival rates for, 22, 25, 37, 40, 41

Bone cancer

- Incidence of, 16, 24, 29
- Mortality of, 11, 17

Bone marrow transplantation

- For leukemia, 324, 328, 330, 346

Brain and central nervous system cancer

- Incidence of, 16, 24, 31
- And leukemia, 324, 328-329
- Mortality of, 11, 17
- Survival rates for, 25

Breast cancer, 42-47, 120-125, 302-309

- Adjuvant chemotherapy for, 42-47; 59-60 (letters)
- Adjuvant endocrine therapy for, 45
- Incidence of, 9, 16, 18, 23, 30, 33-34, 39
- Limited surgery and radiotherapy for early breast cancer, 120-125
- Definition of surgical procedures, 121

- Patient selection, 121-122
 - And role of mammograms in, 121-122
- Mortality of, 9, 11, 14, 17, 19-21
- Role of progesterone receptors in, 45, 302-309
- Survival rates for, 22, 25

C

Cancer in the elderly, 26-41

- In elderly blacks, 255-256 (letters)
- Incidence and survival statistics, 26-41
- Screening the "well elderly," 318-319 (letters)

Cervical cancer

- And the "atypical" Papanicolaou smear, 237-242

Chemotherapy, 42-47, 360-366

- Adjuvant chemotherapy for breast cancer, 42-47; 59-60 (letters)
- For colorectal cancer, 360-366
 - To enhance radiation therapy, 356, 362-363
 - Intra-arterial, 362
 - Surgical adjuvant, 363-364
 - Systemic, 360-362
- And ethical dilemma of clinical trials, 367-369
- For leukemia, 324, 328-346
- For ovarian cancer, 170-172
- For penis cancer, 270
- For prostate cancer, 287-288
- For stomach cancer, 230

Childhood cancer

- Ovarian, 176-183
- Statistics on, 11, 12, 24

Cigarette smoking, 2-8

- Among physicians, dentists, and nurses, 2-8
 - Data from ACS Cancer Prevention Study II, 3-8
 - Factors related to quitting, 4-5

Classics in oncology, 69-82

- Biopsy by needle puncture and aspiration, 69-70 (introduction); 71-82 (classic paper)

Clinical trials, 95-99, 367-369

- Of chemotherapeutic agents, 367-369
- Compared with unproven methods, 368
- Ethical considerations, 95-99, 367-369
- Federal regulations, 97-98

Colorectal cancer, 351-366

- Chemotherapy for, 356, 360-366
- Incidence of, 9, 16, 18, 23, 28, 33-34, 39
- Mortality of, 9, 11, 14-15, 17, 19-20, 217
- Radiation therapy for, 351-359
- Staging of, 353
- Survival rates for, 22, 25, 35, 40

Computed tomography (CT), for detection of pulmonary metastases, 48-58

- CT-directed transthoracic thin-needle aspiration (TTNA), 56-57
- In radiation treatment planning, 57
- Role in evaluating prognostic indicators, 54-56
- Sensitivity, 49-50
- Specificity, 50-53
- And surgery for pulmonary metastasis, 53-54
- Technical improvements, 48-49

Connective tissue cancer

- Incidence of, 16, 29
- Mortality of, 11, 17

D

Dermatologic manifestations of internal cancer, 130-148

- Cutaneous T-cell lymphoma, 130-133
- Histiocytosis X, 133-134
- Hormone-secreting tumors, 143-144
- Inherited syndromes, 140-143
- Kaposi's sarcoma, 135-136
- Lymphomas and leukemias, 137-138
- Mastocytosis, 134-135
- Metastatic carcinoma, 136-137
- Paget's disease, 138-140
- Proliferative and inflammatory dermatoses, 144-147

Dermatoses associated with cancer, proliferative and inflammatory, 144-147

- Acanthosis nigricans, 141, 145
- Bazex's syndrome, 145
- Blistering diseases, 146-147
- Bowen's disease, 145, 259
- Coagulopathies, 144, 146
- Dermatomyositis, 144, 146
- Digital clubbing, 146
- Figurate erythemas, 146
- Hypertrichosis lanuginosa, 145
- Infectious disorders, 145
- Leser-Trélat sign, 141, 145
- Primary amyloidosis, 142, 145
- Punctate palmar keratoses, 145
- Sweet's syndrome, 142, 145

E

Editorials, 83-84, 243-244

- Ethical issues and the cancer patient, 83-84

Progress against cancer? A broader view, 243-244

Editor's note, 316

- Comprehensive Smokeless Tobacco Health Education Act of 1986, 316

Endometrial cancer, 245-253

- Adenomatous hyperplasia and carcinoma in situ, 245-246
- Clinical virulence classification, 248-249
- High-risk patient and menopause, 246-248
- And screening methods, 246, 248
- Hormonal relationships, 251-252
- Individualized treatment, 250-251
- Metastatic, 251
- And the Papanicolaou smear, 245, 248
- Staging of, 248-250
- Technique of early diagnosis, 248

Esophageal cancer

- Incidence of, 16, 23, 28
- Mortality of, 15, 17
- Survival rates for, 22, 25

Ethics and cancer, 83-119; 319-320 (letters); 367-369

- Clinical trials, 95-99, 367-369
- Phase I trials, 367-369
- Referral of patients, 95-99
- And doctor-patient relationship, 98, 368
- Creating a code of ethics, 115-119
- Code of The University of Texas System Cancer Center, 117
- Decision-making in cancer treatment, 85-87, 100-104
- Choice of curative and palliative care, 103-104
- Defining treatment options, 102-104
- Patients with diminished capacity for, 101-102
- Standards for, 100-101
- Ethical issues and the cancer patient, 83-84 (editorial)
- Patient requests in experimental medicine, 62-63 (letters)
- Principle of double effect, 105-106
- Principle of respect for persons, 86-87, 149
- Rights of the cancer patient to know and decide, 85-94
- Advance directives (living wills), 92
- CPR (cardiopulmonary resuscitation) policies, 91-92
- Choice of primary decision-makers, 85-87
- Determining treatment options, 88-90

Disclosing diagnostic and prognostic information, 87-88
Euthanasia, 92-93, 106, 108
Moral framework, 86-87
Providing relief of pain, 90
Spiritual aspects of cancer care, 110-114
Suicide, 105-109

Eye cancer

Incidence of, 16, 31
Retinoblastoma, 24
Mortality of, 17

F

Fecal occult blood test

And double contrast barium enema, 60-62
(letter)

Feedback, 59-64, 126-128, 190-192, 254-256, 317-320, 370-376
Adjuvant chemotherapy, 59-60
Cancer in elderly blacks, 255-256
Chest x-rays, 190-191
Endocavitary irradiation, 63-64
Ethics and cancer, 319-320
Fecal occult blood test, 60-62
Feedback department, 60
Flexible office hours, 317-318
Hormonal therapy, 375-376
Lung cancer: A feminist issue, 126-127
Malignant melanoma, 370-373
Medical ethics, 62-63
Mohs technique, 373-375
Oncologic emergencies, 376
Ostomies, 64
Pap smear, 254-255
Radiation sequelae, 191-192
Screening the "well elderly," 318-319
Smokeless tobacco, 127-128
Transfusion therapy, 254

G

Gallbladder cancer

Incidence of, 29

Gastric cancer

(See Stomach cancer)

H

Histiocytosis X, 133-134

Hormonal therapy, 375-376 (letters)

K

Kaposi's sarcoma, 135-136

Kidney cancer

Incidence of, 16, 24, 30, 34, 39
Mortality of, 11, 17
Survival rates for, 25, 37, 40

L

Laryngeal cancer

Incidence of, 29, 34, 39
Survival rates for, 25, 36, 40

Leukemia, 322-350

And central nervous system, 324, 328-329
Dermatologic manifestations of, 137-138
Diagnostic categories of, 325-327
Incidence of, 9, 16, 18, 24, 31, 33-34, 39, 322
Mortality of, 9, 11, 14-15, 17, 19-21, 322
Signs and symptoms of, 322-323
Survival rates for, 25, 37-38, 40
Treatment of adult acute and chronic, 322-350
Types of, 325-327
Acute lymphoblastic leukemia (ALL), 324-325, 328-329, 331
Prognosis, 328, 333
Acute non-lymphocytic leukemia (ANLL), 325-333
Prognosis, 330, 332-333
Chronic lymphocytic leukemia (CLL), 332, 335-344
Clinical staging and prognostic factors, 332, 334-335
Chronic myelocytic leukemia (CML), 327, 336, 344-346
Prognostic factors, 345-346
Chronic T-cell leukemia, 341-342
Chronic T-cell lymphocytosis, 343-344
Hairy cell leukemia (HCL), 338, 341
Clinical staging and prognostic factors, 338, 341
Lymphosarcoma cell leukemia, 341
Prolymphocytic leukemia, 337-338

Liver cancer

Incidence of, 16, 23-24, 29
Mortality of, 14-15, 17
Survival rates for, 22, 25

Lung cancer

Chest x-rays for, 190-191 (letters)
A feminist issue, 126-127 (letters)
Incidence of, 9, 16, 18, 23, 29, 33-34, 39
Mortality of, 9, 11, 14-15, 17, 19-21
Survival rates for, 22, 25, 36, 40

Lymphomas

Cutaneous T-cell, 130-133
Dermatologic manifestations of, 137-138
Incidence of, 9, 16, 24, 31, 34, 39
Mortality of, 9, 11, 17
Survival rates for, 25, 37, 40

M

Mammograms

Role of, in patient selection for limited

surgery and irradiation, 121-122

Manner, Harold W., 185-189 (unproven methods)

Martin, Hayes E., 69-70 (biography)

Mastocytosis, 134-135

Melanoma, malignant

Early detection of, 370-373 (letters)
Incidence of, 23, 29

Metabolic cancer therapy, 185-189
(unproven methods)

Metastases, 48-58

Cutaneous, 136-137
Ovarian, 169-170, 183
Penis, 261
Pulmonary occult, 48-58
And role of surgery for, 53-54
Stomach, 223-225, 233

Mohs technique, 373-374 (letter)

N

National Institutes of Health Consensus Development Conference Statements, 42-47, 310-316

On adjuvant chemotherapy for breast cancer, 42-47
On smokeless tobacco, 310-316

Nose cancer

Incidence of, 29

O

Oncologic emergencies, 376 (letter)

Opinion, 367-369

The ethical dilemma of Phase I clinical trials, 367-369

Oral cancer

Incidence of, 9, 16, 18, 28
Mortality of, 9, 17, 19-20
And smokeless tobacco, 312-313
Survival rates for, 25

Ostomies (letter), 64

Ovarian cancer, 149-184

Chemotherapy for, 170-172
In children, 176-183
Classification of, 157-160, 177
Clinical manifestations, 152-153
Diagnosis of, 149, 153-157, 176-177
Complete workup, 154
Cytogenetics, 156-157

Exploratory laparotomy, 154

Masquerading as an umbilical hernia, 153

Palpation, 154

Pelvic findings, 153-154

Tumor-specific antigens, 155-156

Diagnosis and management of an adnexal mass, 163-164

In pregnancy, 167-168, 180

Early detection and prevention, 156-157

Postmenopausal palpable ovary syndrome, 157

Significance of unexplainable gastrointestinal symptoms in, 152-153, 183

Epidemiology of, 150-152

Differences among ethnic groups, 151-152

Of epithelial and stromal origin, 178

Extended surgery and pelvic exenteration for, 166

Flow cytometry, 174

Germ cell tumors, 168-169, 178, 180-181

Gonadal stromal tumors, 169, 181-182

Gonadoblastoma, 169, 181

Immunotherapy for, 172

Incidence of, 9, 16, 23, 30, 34, 39, 150, 156
Indications for removal of the bulk of tumor, 166-167

In vitro chemosensitivity testing, 172-174

Management of, 164-165

In pregnancy, 168, 180

Metastatic, 169-170, 183

Mortality of, 9, 11, 14, 17, 150

Node dissection for, 166

Radioactive isotopes for, 166

Radiation therapy for, 170

Rupture of tumor, 165-166

Sarcoma, 182

Second-look operation for, 174-176

Staging of, 160-163, 179

Low malignant potential (LMP) tumors, 161-162

Ovarian mesothelioma, 162-163

Survival rates for, 22, 25, 37, 40, 149, 152

Treatment, 149-150, 161-162, 164-172, 174-176, 178, 180-183

Of epithelial cancers, 165, 178

Of nonepithelial cancer, 168-169, 178, 180-182

P

Paget's disease, 138-140

Pain, cancer, 194-215

Epidemiology of, 194-195

Ethics and providing relief of, 90, 197, 202

Management of, 194, 198

Supportive care, 211

Therapeutic approaches, 198-211

Anesthetic procedures, 201, 209-210

Behavioral approaches, 211
Drug therapy, 200, 202-209
Neurosurgical procedures, 199,
210-211
Types of, 195-198

Pancreatic cancer

Incidence of, 9, 16, 19, 29, 33-34, 39
Mortality of, 9, 11, 14-15, 17, 19, 217
Survival rates for, 25, 35, 40

Papanicolaou smear, 237-242

ACS guidelines for, 254-255 (letters)
Management of the patient with the
"atypical," 237-242

Pellegrino, Edmund, 84 (biography)

Penis cancer, 258-273

Cancerous lesions, 259-261
Basal cell carcinoma, 260
Carcinoma in situ, 259-260
Melanoma, 260
Mesenchymal tumors, 260-261
Metastatic tumors, 261
Squamous carcinoma, 260
Chemotherapy for, 270
Ilioinguinal node dissection, 268-270
Incidence of, 30
Penectomy, 262-263
Precancerous lesions, 258-259
Balanitis xerotica obliterans, 259
Bowen's disease, 259
Buschke-Loewenstein tumor, 259
Erythroplasia of Queyrat, 258-259
Leukoplakia, 258
Radiation therapy for, 264-265, 268,
270-271
Staging of, 261-262
Survival rates for, 264-265, 267, 271
Treatment, 261-268, 270-271
Guidelines, 270-271
Of primary lesions, 264-265
Of regional lymph nodes, 265-268
Of squamous carcinoma, 261-265

Pharyngeal cancer

Incidence of, 16, 28
Mortality of, 17
Survival rates for, 25

Progesterone receptors (PRs), role in breast cancer, 302-309

In advanced breast cancer therapy, 305,
307
Consistency of repeated PR assays,
306-308
In early breast cancer therapy, 303, 305,
307
Significance of changes in PR status,
307-308
Versus estrogen receptors, 302-304

Prostate cancer, 274-292

Diagnosis and staging, 275-278
Epidemiology of, 274-275
Incidence of, 9, 16, 18, 23, 30, 33-34, 39,
274-275
Mortality of, 9, 11, 15, 17, 19-21
Pathology of, 275
Stages of, 278-279, 281
Treatment, 279-289
Chemotherapy, 287-288
Hormone therapy, 282-287
Palliative therapy, 288-289
Survival rates for, 22, 25, 37, 40, 277, 289

R

Radiation therapy, 120-125, 351-359

For early breast cancer, 120-125
For colorectal cancer, 351-359
Adjuvant postoperative irradiation,
352-354
Combined with chemotherapy, 356,
362-363
Historical perspective, 351-352
Intraoperative radiation, 356-357
Preoperative irradiation, 354
Present day, 352-356
Primary irradiation, 354-356
"Sandwich" technique, 354-355
Endocavitary irradiation for
adenocarcinoma of the rectum, 63-64
(letters)
For leukemia, 324, 331, 337-346
For ovarian cancer, 170
For penis cancer, 264-265, 268, 270-271
For prostate cancer, 279-283, 285
Sequelae in childhood retinoblastoma
patients, 191-192 (letters)
For stomach cancer, 230

S

Skin cancer

Early detection of malignant melanoma,
372-375 (letters)
Incidence of, 9, 16, 23, 29
Mortality of, 9, 11, 17
Survival rates for, 22, 25

Small intestine cancer

Incidence of, 16, 28
Mortality of, 17

Smokeless tobacco, 127-128 (letters); 310-316

Behavioral consequences, 314-315
Comprehensive Smokeless Tobacco
Health Education Act of 1986, 316
Current trends in use, 311-312
And need for further research, 315

And risk of oral or other cancers, 312-313
And risk of periodontal disease or other
oral and health problems, 313-314

Soft tissue cancer
Incidence of, 24

Spiritual aspects of cancer care, 110-114

Statistics, cancer, 9-41
(See Cancer in the elderly, Childhood
cancer, and specific sites)

Stomach cancer, 216-236
Chemotherapy for, 230, 234
Detection and diagnosis, 218-219,
233-234
Epidemiology and etiology of, 216-218
Follow-up, 231
Incidence of, 16, 18, 23, 28, 33-34, 39,
216
Mortality of, 11, 14-15, 17, 19-21,
216-217
Operative management, 222-231
Choice of operation, 224, 226-227
Lymphatic spread, 223-225, 233
Nutritional consequences of
gastrectomy, 228-229
Palliative operations, 227-229
Reconstruction after gastrectomy, 228,
230
Pathology of, 221-223
Preoperative management, 218-220
Prognosis, 231-233
Radiation therapy for, 230
Staging of, 220-221
Survival rates for, 22, 25, 35, 40, 229,
233-234

Suicide and the cancer patient, 105-109

Surgery, 120-125
For early breast cancer, 120-125
For colon cancer, 9-10
And adjuvant chemotherapy, 363, 364
For leukemia, 337, 338-341, 343, 346
For ovarian cancer, 164-170, 174-176,
178, 180-183
For penis cancer, 258-271
For prostate cancer, 279-283, 285
For pulmonary metastases, 53-54
Role of computed tomography in, 53-54

Sympathetic nervous system cancer
Incidence of, 24

Syndromes, inherited, 139-143
Cowden's disease (multiple hamartoma
syndrome), 139-141
Cronkhite-Canada syndrome, 141
Gardner's syndrome, 139, 141
Howell-Evans syndrome (tylosis), 140, 142

Immunodeficiency syndromes, 143
Multiple mucosal neuromas syndrome,
140, 142
Peutz-Jeghers syndrome, 139, 141
Torre's syndrome, 141
Von Recklinghausen's disease
(neurofibromatosis), 140, 142-143

T

Testicular cancer
Incidence of, 16, 23, 30
Mortality of, 17
Survival rates for, 22, 25

Thyroid cancer
Incidence of, 16, 31
Mortality of, 17
Survival rates for, 25

Transfusion therapy
Irradiated blood products, 254 (letters)

Treatment of cancer
(See also, specific sites)
Ethics and, 85-109
Myths and fallacies, 293-301
Pain, 194-215

Tumors, hormone-secreting, 143-144
Carcinoid syndrome, 143-144
Ectopic ACTH syndrome, 143
Glucagonoma syndrome, 144

U

**Unproven methods of cancer
management, 185-189**
Compared with clinical trials, 368
Helping your patients deal with
questionable cancer treatments,
293-301
The metabolic cancer therapy of Harold W.
Manner, Ph.D., 185-189

Uterine cancer
Incidence of, 9, 16, 18, 23, 30, 33-34, 36,
39
Mortality of, 9, 11, 14, 17, 19-21
Survival rates for, 22, 25, 36, 40

V

Vaginal cancer
Incidence of, 30

Vulvar cancer
Incidence of, 30

W

Well elderly, screening for cancer, 318-319
(letters)

X

X-rays, chest, 190-191 (letters)

Author Index, 1986

Vol. 36, Nos. 1-6

Alt J, 115-119

Baker HW, 69-70
Baranovsky A, 26-41; 256 (letter)
Barber HRK, 149-184
Bowen JM, 115-119
Braun M, 83-84
Brody BA, 62-63 (letter)
Buzas JW, 370 (letter)

Callahan A, 373-375 (letter)
Chernish SM, 60-62 (letter)
Childress JF, 85-94
Clark GM, 302-309
Clayton OW, 190 (letter)
Coltman CA, Jr., 59-60 (letter)
Coppola V, Jr., 60 (letter)
Crispen JF, 320 (letter)

deKernion J, 258-273

Eddy DM, 190-191, 318-319, 373 (letters)
Ellis EB, 71-82
Engelhardt HT, Jr., 105-109

Foley KM, 194-215
Fragoso M, 254 (letter)

Garfinkel L, 2-8
Gladstone GC, 370 (letter)
Gorski RC, 372 (letter)
Greenberg E, 375-376 (letter)
Griffiths EK, 126 (letter)
Gunderson LL, 351-359
Gusberg SB, 245-253, 255 (letter)

Haley HB, 62-63 (letter)
Han T, 322-350
Harris JR, 120-125
Hartman LC, 370-371 (letter)
Hellman S, 120-125
Henderson ES, 322-350
Hoffman A, 127 (letter)
Holleb AI, 66-68, 83-84, 243-244
Huben RP, 274-292
Huff RW(E), 127 (letter)
Huh YO, 254 (letter)

Jarvis W, 293-301
Jones WB, 237-242

Kinne DW, 120-125
Kolenda BJ, 115-119
Kushner R, 60 (letter)

Lawrence W, Jr., 216-236
Lescoe RJ, 63 (letter)
Letton AH, 127 (letter)
Levine RJ, 95-99
Lichtenstein GA, 372 (letter)
Lichtiger B, 254 (letter)
Long JC, 319 (letter)
Loui WWS, 375 (letter)
Lubera J, 9-25
Lynn J, 100-104

Maglinte DDT, 60-62 (letter)
Markman M, 367-369
Martin HE, 71-82
Martin RS, 115-119
Maughan GM, 254-255 (letter)
McElvein RB, 376 (letter)
McGuire WL, 302-309
Meadows AT, 192 (letter)
Mellette SJ, 317-318 (letter)
Micetich KC, 63 (letter)
Miller CB, 318 (letter)
Miller JM, 255-256 (letter)
Miller RE, 60-62 (letter)
Murphy GP, 274-292
Myers MH, 26-41, 256 (letter)

O'Connell MJ, 360-366
Osborne CK, 59-60 (letter)

Persky L, 258-273
Putman CE, 48-58

Reay-Young PS, 127-128 (letter)
Reifler DM, 191-192 (letter)
Reiser SJ, 115-119
Richmond JB, 126-127 (letter)
Roda PI, 317 (letter)

Saigo PE, 237-242
Schoene-Seifert B, 85-94
Seagren SL, 370 (letter)
Shullenberger CC, 115-119
Silverberg E, 9-25
Sischy B, 63-64 (letter), 351-359
Squier CA, 128 (letter)
Stellman SD, 2-8
Stucke JK, 64 (letter)

Thiers BH, 130-148
Thomasma DC, 63 (letter)
Thulin BW, 127 (letter)

van Eys J, 115-119
Vastyan EA, 110-114
von Eschenbach AC, 115-119
Wellner LJ, 48-58

